The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.

MLA

Soldat-Stanković, V., et al. “The Effect of Metformin and Myoinositol on Metabolic Outcomes in Women with Polycystic Ovary Syndrome: Role of Body Mass and Adiponectin in a Randomized Controlled Trial.” Journal of Endocrinological Investigation, vol. 45, no. 3, Mar. 2022, pp. 583–95. EBSCOhost, https://doi.org/10.1007/s40618-021-01691-5.

APA

Soldat-Stanković, V., Popović-Pejičić, S., Stanković, S., Prtina, A., Malešević, G., Bjekić-Macut, J., Livadas, S., Ognjanović, S., Mastorakos, G., Micić, D., & Macut, D. (2022). The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. Journal of Endocrinological Investigation, 45(3), 583–595. https://doi.org/10.1007/s40618-021-01691-5

Chicago

Soldat-Stanković, V, S Popović-Pejičić, S Stanković, A Prtina, G Malešević, J Bjekić-Macut, S Livadas, et al. 2022. “The Effect of Metformin and Myoinositol on Metabolic Outcomes in Women with Polycystic Ovary Syndrome: Role of Body Mass and Adiponectin in a Randomized Controlled Trial.” Journal of Endocrinological Investigation 45 (3): 583–95. doi:10.1007/s40618-021-01691-5.